Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).
- DOI
- 10.1111/pde.70177
- Published
- 2026 May-Jun
- Container
- Pediatric dermatology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/pde.70177,
title = {Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05\% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).},
author = {Eichenfield LF and Gonzalez ME and Boguniewicz M and Funk T and Hebert AA and Prajapati VH and Kindred C and Serrao R and Swanson L and Krupa D and Snyder S and Seal MS and Hanna D and Burnett P and Berk DR},
year = {2026},
journal = {Pediatric dermatology},
doi = {10.1111/pde.70177},
url = {https://doi.org/10.1111/pde.70177}
}RIS
TY - JOUR TI - Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE). AU - Eichenfield LF AU - Gonzalez ME AU - Boguniewicz M AU - Funk T AU - Hebert AA AU - Prajapati VH AU - Kindred C AU - Serrao R AU - Swanson L AU - Krupa D AU - Snyder S AU - Seal MS AU - Hanna D AU - Burnett P AU - Berk DR PY - 2026 JO - Pediatric dermatology DO - 10.1111/pde.70177 UR - https://doi.org/10.1111/pde.70177 ER -
APA
LF, E., ME, G., M, B., T, F., AA, H., VH, P., C, K., R, S., L, S., D, K., S, S., MS, S., D, H., P, B., & DR, B. (2026). Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).. Pediatric dermatology. https://doi.org/10.1111/pde.70177
Source records
- pubmed · retrieved 2026-09-24T23:44:08.157Z